Evaluasi Penggunaan Ramipril dan Candesartan pada Pasien Rawat Inap COVID-19 dengan Komorbid Hipertensi di RSUD Dr. Moewardi

Hypertension is the most common comorbid in patients infected by COVID-19. Drugs often given for treatment of hypertension, namely ramipril, and candesartan, are thought to increase development COVID-19 because angiotensin-converting enzyme inhibitors (ACEI) angiotensin receptor blockers (ARBs) expression ACE-2, which binding site SARS-CoV-2. This study aims analyze effect using ramipril candesartan on healing hospitalized with hypertension at RSUD dr. Moewardi 2020. was conducted retrospectively. The results were presented descriptively used medical record data Using affects patient recovery terms length stay (LOS), symptom relief, RT-PCR test results. Analysis research SPSS Spearman correlation test. showed that there a fairly strong relationship between use LOS, show can improve hypertension. ACEI ARB drugs have not been proven worsen patient's condition so their be continued.